Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 2,800,000 shares, a growth of 1,100.2% from the September 15th total of 233,300 shares. Approximately 12.8% of the company’s stock are short sold. Based on an average daily volume of 936,000 shares, the short-interest ratio is currently 3.0 days.

Wall Street Analyst Weigh In

Separately, Benchmark reiterated a “speculative buy” rating and set a $2.00 price target on shares of Cardio Diagnostics in a report on Tuesday, August 27th.

Cardio Diagnostics Price Performance

Shares of CDIO stock opened at $0.20 on Friday. The stock’s 50 day simple moving average is $0.33 and its 200 day simple moving average is $0.60. Cardio Diagnostics has a twelve month low of $0.17 and a twelve month high of $3.56.

Cardio Diagnostics (NASDAQ:CDIO) last posted its earnings results on Monday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.07. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.13 million. Cardio Diagnostics had a negative net margin of 22,358.43% and a negative return on equity of 312.97%. Analysts anticipate that Cardio Diagnostics will post -0.55 earnings per share for the current fiscal year.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.